Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats

Strong evidence supports the hypothesis that synapse damage and memory impairment in early Alzheimer disease (AD) might be due to synaptic failure caused by amyloid beta oligomers (AβOs). We demonstrated the preclinical efficacy of a single-chain variable-fragment (scFv) antibody NUsc1 that selectiv...

Full description

Autores:
Colettis, Natalia
Oberholzer, Maria Victoria
Cercato, Magali
Habif, Martin
Selles, Maria Clara
Salas, Daniela
Sebollela, Adriano
Klein, William-L.
Epstein, Alberto
Salvetti, Anna
Ferreira, Sergio-T.
Jerusalinsky, Diana
Tipo de recurso:
Article of journal
Fecha de publicación:
2023
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/10179
Acceso en línea:
https://hdl.handle.net/11323/10179
https://repositorio.cuc.edu.co/
Palabra clave:
LTM
Alzheimer’s disease
Gene therapy
ScFv
Single chain antibody fragment
Aβ oligomer
Memoria de larga duración MLD
Enfermedad de Alzheimer
Terapia génica
Fragmento de anticuerpo de cadena simple
Oligómeros Aβ
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
id RCUC2_e6d8a17a3f92ea61ca5e925d5d3f8316
oai_identifier_str oai:repositorio.cuc.edu.co:11323/10179
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.none.fl_str_mv Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
dc.title.translated.none.fl_str_mv Recuperación de la memoria mediante terapia génica con un fragmento de anticuerpo selectivo para oligómeros de Aβ en un modelo de Alzheimer en ratas
title Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
spellingShingle Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
LTM
Alzheimer’s disease
Gene therapy
ScFv
Single chain antibody fragment
Aβ oligomer
Memoria de larga duración MLD
Enfermedad de Alzheimer
Terapia génica
Fragmento de anticuerpo de cadena simple
Oligómeros Aβ
title_short Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
title_full Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
title_fullStr Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
title_full_unstemmed Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
title_sort Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats
dc.creator.fl_str_mv Colettis, Natalia
Oberholzer, Maria Victoria
Cercato, Magali
Habif, Martin
Selles, Maria Clara
Salas, Daniela
Sebollela, Adriano
Klein, William-L.
Epstein, Alberto
Salvetti, Anna
Ferreira, Sergio-T.
Jerusalinsky, Diana
dc.contributor.author.none.fl_str_mv Colettis, Natalia
Oberholzer, Maria Victoria
Cercato, Magali
Habif, Martin
Selles, Maria Clara
Salas, Daniela
Sebollela, Adriano
Klein, William-L.
Epstein, Alberto
Salvetti, Anna
Ferreira, Sergio-T.
Jerusalinsky, Diana
dc.subject.proposal.eng.fl_str_mv LTM
Alzheimer’s disease
Gene therapy
ScFv
Single chain antibody fragment
Aβ oligomer
topic LTM
Alzheimer’s disease
Gene therapy
ScFv
Single chain antibody fragment
Aβ oligomer
Memoria de larga duración MLD
Enfermedad de Alzheimer
Terapia génica
Fragmento de anticuerpo de cadena simple
Oligómeros Aβ
dc.subject.proposal.spa.fl_str_mv Memoria de larga duración MLD
Enfermedad de Alzheimer
Terapia génica
Fragmento de anticuerpo de cadena simple
Oligómeros Aβ
description Strong evidence supports the hypothesis that synapse damage and memory impairment in early Alzheimer disease (AD) might be due to synaptic failure caused by amyloid beta oligomers (AβOs). We demonstrated the preclinical efficacy of a single-chain variable-fragment (scFv) antibody NUsc1 that selectively targets a subpopulation of AβOs; NUsc1 prevented AβO-induced inhibition of long-term potentiation in hippocampal slices and short-term memory impairment in mice. Since specific targeting of AβOs by NUsc1 may be a substantial improvement in target engagement and efficacy for AD therapy, we developed an adeno-associated virus (AAV) vector to drive neuronal expression of NUsc1 within the brain. AAV-NUsc1 rescued short-term memory (STM) for objects and congeners interaction in mice AD models. Purpose: In heterozygous McGill-R-Thy1-APP transgenic (Tg+/–) rat model of AD, progressive amyloid pathology is accompanied by cognitive impairment involving long-term memory (LTM) decline. LTM in a novel-object-recognition (NOR) task was impaired in 4-month-old (Tg+/–) male rats, suggesting that they are unable to form/evoke such discriminative memories. Hence, we investigated if AAV-NUsc1 treatment could rescued this memory. Methods: 10-12 weeks-old either Tg or wild type male rats were i.c.v. infused with AAV-NUsc1. Two months later, short-term exploratory behavior, habituation to an open field (OF), object discrimination and LTM for objects were assessed. Results: AAV-NUsc1 treated Tg rats were able to successfully perform the task 24 h after training, denoting recovery of LT discrimination capacity and LTM formation. Wild type rats successfully performed the task either treated or not with AAV-NUsc1. Also, exploration and short-term habituation to an open field was preserved in Tg+/– rats either treated or not. Conclusions: Our present and previous results suggest that AAV-NUsc1 represents a significant advance in gene therapy, supporting the feasibility of immunotherapy using viral vector-mediated NUsc1 gene delivery as a potential therapeutic approach in AD.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-05-24T22:25:46Z
dc.date.available.none.fl_str_mv 2023-05-24T22:25:46Z
dc.date.issued.none.fl_str_mv 2023
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Colettis, N.-C., Oberholzer, M.-V., Cercato, M.-C., Habif, M., Selles, M.-C., Salas, D.-A., Silva-Sebollela, A., Lee-Klein, W., Epstein, A.-L., Salvetti, A., Texeira-Ferreira, S. & Jerusalinsky, D.-A. (2023). Memory recovery through gene therapy with an antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats. Journal of Applied Cognitive Neuroscience, 3(2), e00344688. https://doi.org/10.17981/JACN.4.1.2023.02
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/11323/10179
dc.identifier.doi.none.fl_str_mv 10.17981/JACN.4.1.2023.02
dc.identifier.eissn.spa.fl_str_mv 2745-0031
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC – Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
identifier_str_mv Colettis, N.-C., Oberholzer, M.-V., Cercato, M.-C., Habif, M., Selles, M.-C., Salas, D.-A., Silva-Sebollela, A., Lee-Klein, W., Epstein, A.-L., Salvetti, A., Texeira-Ferreira, S. & Jerusalinsky, D.-A. (2023). Memory recovery through gene therapy with an antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats. Journal of Applied Cognitive Neuroscience, 3(2), e00344688. https://doi.org/10.17981/JACN.4.1.2023.02
10.17981/JACN.4.1.2023.02
2745-0031
Corporación Universidad de la Costa
REDICUC – Repositorio CUC
url https://hdl.handle.net/11323/10179
https://repositorio.cuc.edu.co/
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournal.spa.fl_str_mv Journal of Applied Cognitive Neuroscience
dc.relation.references.spa.fl_str_mv Ahmad, Z.; Yeap, S.; Ali, A.; Ho, W.; Alitheen, N. & Hamid, M. (2012). ScFv antibody: Principles and clinical application. Clinical and Developmental Immunology, 1–16. https://doi.org/10.1155/2012/980250
Akkerman, S.; Blokland, A.; Reneerkens, O.; Van Goethem, N.; Bollen, E.; Gijselaers, H.; Lieben, C.; Steinbusch, H. & Prickaerts, J. (2012). Object recognition testing: Methodological considerations on exploration and discrimination measures. Behavioural Brain Research, 232(2), 335–347. https://doi.org/10.1016/J.BBR.2012.03.022
Chabrier, M.; Cheng, D.; Castello, N.; Green, K. & LaFerla, F. (2014). Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer’s disease. Neurobiology of Disease, 64, 107–117. https://doi.org/10.1016/j.nbd.2014.01.007
Do Carmo, S. & Cuello, A. (2013). Modeling Alzheimer’s disease in transgenic rats. Molecular Neurodegeneration, 8(1), 1–11. https://doi.org/10.1186/1750-1326-8-37
Dunbar, C.; High, K.; Joung, J.; Kohn, D.; Ozawa, K. & Sadelain, M. (2018). Gene therapy comes of age. Science, 359(6372), 1–10. https://doi.org/10.1126/SCIENCE.AAN4672
España, J.; Giménez-Llort, L.; Valero, J.; Miñano, A.; Rábano, A.; Rodriguez-Alvarez, J.; LaFerla, F. & Saura, C. A. (2010). Intraneuronal β-Amyloid Accumulation in the Amygdala Enhances Fear and Anxiety in Alzheimer’s Disease Transgenic Mice. Biological Psychiatry, 67(6), 513–521. https://doi.org/10.1016/j.biopsych.2009.06.015
Ferreira, S. & Klein, W. (2011). The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiology of Learning and Memory, 96(4), 529–543. https://doi.org/10.1016/J.NLM.2011.08.003
Ferrer, I.; Rovira, M.; Sanchez, M.; Rey, M. & Costa-Jussá, F. (2004). Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer’s Disease. Brain Pathology, 14(1), 11–20. https://doi.org/10.1111/j.1750-3639.2004.tb00493.x
Fischell, J. & Fishman, P. (2021). A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. Frontiers in Neuroscience, 15, 1–20. https://doi.org/10.3389/fnins.2021.747726
Fukumoto, H.; Tokuda, T.; Kasai, T.; Ishigami, N.; Hidaka, H.; Kondo, M.; Allsop, D. & Nakagawa, M. (2010). High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. The FASEB Journal, 24(8), 2716–2726. https://doi.org/10.1096/FJ.09-150359
Fuller, J.; Stavenhagen, J. & Teeling, J. (2014). New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Frontiers in Neuroscience, 8, 1–10. https://doi.org/10.3389/FNINS.2014.00235
Galeano, P.; Martino, P.; Do Carmo, S.; Blanco, E.; Rotondaro, C.; Capani, F.; Castaño, E.; Cuello, A. & Morelli, L. (2014). Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer’s disease. Frontiers in Behavioral Neuroscience, 8, 1–15. https://doi.org/10.3389/fnbeh.2014.00321
Georganopoulou, D.; Chang, L.; Nam, J.; Thaxton, C.; Mufson, E.; Klein, W. & Mirkin, C. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proceedings of the National Academy of Sciences, 102(7), 2273–2276. https://doi.org/10.1073/pnas.0409336102
Gong, Y.; Chang, L.; Viola, K.; Lacor, P.; Lambert, M.; Finch, C.; Krafft, G. & Klein, W. (2003). Alzheimer’s disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences, 100(18), 10417–10422. https://doi.org/10.1073/PNAS.1834302100
Habif, M.; Do Carmo, S.; Báez, M.; Colettis, N.; Cercato, M.; Salas, D.; Acutain, M.; Sister, C.; Berkowicz, V.; Canal, M.; González, T.; Cuello, A. & Jerusalinsky, D. (2021). Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer’s-Like Brain Amyloidosis. Frontiers in Aging Neuroscience, 12, 1–18. https://doi.org/10.3389/fnagi.2020.585873
Holliger, P. & Hudson, P. (2005). Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23(9), 1126–1136. https://doi.org/10.1038/nbt1142
Huang, L.; Su, X. & Federoff, H. (2013). Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. International Journal of Molecular Sciences, 14(9), 19109–19127. https://doi.org/10.3390/IJMS140919109
Iulita, M.; Allard, S.; Richter, L.; Munter., L.; Ducatenzeiler, A.; Weise, C.; Do Carmo, S.; Klein, W.; Multhaup, G. & Cuello, A. (2014). Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Communications, 2, 1–17. https://doi.org/10.1186/2051-5960-2-61
Larson, M. & Lesné, S. (2012). Soluble Aβ oligomer production and toxicity. Journal of Neurochemistry, 120(SUPPL. 1), 125–139. https://doi.org/10.1111/j.1471-4159.2011.07478.x
Leon,W.; Canneva,F.;Partridge, V.; Allard,S.;Ferretti,M.;DeWilde, A.; Vercauteren, F.; Atifeh, R.; Ducatenzeiler, A.; Klein, W.; Szyf, M.; Alhonen, L. & Cuello, A. (2010). A Novel Transgenic Rat Model with a Full Alzheimer’s-Like Amyloid Pathology Displays Pre-Plaque Intracellular Amyloid-β-Associated Cognitive Impairment. Journal of Alzheimer’s Disease, 20(1), 113–126. https://doi.org/10.3233/JAD-2010-1349
Monnier, P.; Vigouroux, R. & Tassew, N. (2013). In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies, 2(2), 193–208. https://doi.org/10.3390/antib2020193
Motulsky, H. & Beutler, E. B. (1989). GraphPad Prism (version 8.0.2) [Software]. GraphPad Software, Inc. https://www.graphpad.com/
Mucke, L. & Selkoe, D. (2012). Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harbor Perspectives in Medicine, 2(7), 1–18. https://doi.org/10.1101/cshperspect.a006338
Nicoll, J.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H. & Weller, R. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Medicine, 9(4), 448–452. https://doi.org/10.1038/nm840
Orgogozo, J.-M.; Gilman, S.; Dartigues, J.-F.; Laurent, B.; Puel, M.; Kirby, L.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.; Boada, M.; Frank, A. & Hock, C. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology, 61(1), 46–54. https://doi.org/10.1212/01.WNL.0000073623.84147.A8
Paxinos, G. & Watson, C. (2013). Rat brain in stereotaxic coordinates [7 ed.]. Elsevier.
Pimentel, L.; Allard, S.; Do Carmo, S.; Weinreb, O.; Danik, M.; Hanzel, C.; Youdim, M. & Cuello, A. (2015). The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 47(2), 373–383. https://doi.org/10.3233/JAD-143126
Sebollela, A.; Cline, E.; Popova, I.; Luo, K.; Sun, X.; Ahn, J.; Barcelos, M.; Bezerra, V.; Lira e Silva, N.; Patel, J.; Pinheiro, N.; Qin, L.; Kamel, J.; Weng, A.; DiNunno, N.; Bebenek, A.; Velasco, P.; Viola, K.; Lacor, P.; Ferreira, S. & Klein, W. (2017). A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers. Journal of Neurochemistry, 142(6), 934–947. https://doi.org/10.1111/JNC.14118
Selkoe, D. & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/EMMM.201606210
Selles, M.; Fortuna, J.; Cercato, M.; Santos, L.; Domett, L.; Bitencourt, A.; Carraro, M.; Souza, A.; Janickova, H.; Azevedo, C.; Campos, H.; De Souza, J.; AlvesLeon, S.; Prado, V.; Prado, M.; Epstein, A.; Salvetti, A.; Longo, B.; Arancio, O.; Klein, W.; Sebollela, A.; De Felice, F.; Jerusalinsky, D. & Ferreira, S. (2022). AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapse s and rescues memory in Alzheimer models. Molecular Therapy, 31(2), 409–419. https://doi.org/10.1016/j.ymthe.2022.11.002
Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O’Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M.; Quintero-Monzon, O.; Scannevin, R.; Arnold, H.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R. & Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323
Tomiyama, T.; Matsuyama, S.; Iso, H.; Umeda, T.; Takuma, H.; Ohnishi, K.; Ishibashi, K.; Teraoka, R.; Sakama, N.; Yamashita, T.; Nishitsuji, K.; Ito, K.; Shimada, H.; Lambert, M.; Klein, W. & Mori, H. (2010). A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. Journal of Neuroscience, 30(14), 4845–4856. https://doi.org/10.1523/JNEUROSCI.5825-09.2010
Tran, T.; Kim, S.; Gallo, C.; Amaya, M.; Kyees, J. & Narayanaswami, V. (2013). Biochemical and biophysical characterization of recombinant rat apolipoprotein E: Similarities to human apolipoprotein E3. Archives of Biochemistry and Biophysics, 529(1), 18–25. https://doi.org/10.1016/j.abb.2012.10.007
Van Dyck, C.; Swanson, C.; Aisen, P.; Bateman, R.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L. & Iwatsubo, T. (2022). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Velasco, P.; Heffern, M.; Sebollela, A.; Popova, I.; Lacor, P.; Lee, K.; Sun, X.; Tiano, B.; Viola, K.; Eckermann, A.; Meade, T. & Klein, W. (2012). Synapse-Binding Subpopulationsof Aβ OligomersSensitive to Peptide Assembly Blockers and scFv Antibodies. ACS Chemical Neuroscience, 3(11), 972–981. https://doi.org/10.1021/cn300122k
dc.relation.citationendpage.spa.fl_str_mv 16
dc.relation.citationstartpage.spa.fl_str_mv 1
dc.relation.citationissue.spa.fl_str_mv 1
dc.relation.citationvolume.spa.fl_str_mv 4
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
https://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 16 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Corporación Universidad de la Costa
dc.publisher.place.spa.fl_str_mv Colombia
dc.source.spa.fl_str_mv https://revistascientificas.cuc.edu.co/JACN/article/view/4688
institution Corporación Universidad de la Costa
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/b09acb4a-40c9-4d6c-9545-576e9449b2c0/download
https://repositorio.cuc.edu.co/bitstreams/47ec96ef-f233-48b9-8c92-a7ebb8a1a3a4/download
https://repositorio.cuc.edu.co/bitstreams/deb65333-c02a-4921-a6f2-20c42001f4f1/download
https://repositorio.cuc.edu.co/bitstreams/a39cb0fe-5f25-4266-8f7a-198694d29706/download
bitstream.checksum.fl_str_mv 191bd38f77dd3bf5ba3beb3aca987d25
2f9959eaf5b71fae44bbf9ec84150c7a
44220bf60ca5561946723e077b05af06
af32d53618119e0be2efc17b0743ad64
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1811760783957164032
spelling Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)Copyright (c) 2023 Natalia-Claudia Colettis, Maria-Victoria Oberholzer, Magali Cercato, Martin Habif, Maria-Clara Selles, Daniela Salas, Adriano Sebollela, William-L. Klein, Alberto-L. Epstein, Anna Salvetti, Sergio-T. Ferreira, Diana Jerusalinskyhttps://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Colettis, NataliaOberholzer, Maria VictoriaCercato, MagaliHabif, MartinSelles, Maria ClaraSalas, DanielaSebollela, AdrianoKlein, William-L.Epstein, AlbertoSalvetti, AnnaFerreira, Sergio-T.Jerusalinsky, Diana2023-05-24T22:25:46Z2023-05-24T22:25:46Z2023Colettis, N.-C., Oberholzer, M.-V., Cercato, M.-C., Habif, M., Selles, M.-C., Salas, D.-A., Silva-Sebollela, A., Lee-Klein, W., Epstein, A.-L., Salvetti, A., Texeira-Ferreira, S. & Jerusalinsky, D.-A. (2023). Memory recovery through gene therapy with an antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in rats. Journal of Applied Cognitive Neuroscience, 3(2), e00344688. https://doi.org/10.17981/JACN.4.1.2023.02https://hdl.handle.net/11323/1017910.17981/JACN.4.1.2023.022745-0031Corporación Universidad de la CostaREDICUC – Repositorio CUChttps://repositorio.cuc.edu.co/Strong evidence supports the hypothesis that synapse damage and memory impairment in early Alzheimer disease (AD) might be due to synaptic failure caused by amyloid beta oligomers (AβOs). We demonstrated the preclinical efficacy of a single-chain variable-fragment (scFv) antibody NUsc1 that selectively targets a subpopulation of AβOs; NUsc1 prevented AβO-induced inhibition of long-term potentiation in hippocampal slices and short-term memory impairment in mice. Since specific targeting of AβOs by NUsc1 may be a substantial improvement in target engagement and efficacy for AD therapy, we developed an adeno-associated virus (AAV) vector to drive neuronal expression of NUsc1 within the brain. AAV-NUsc1 rescued short-term memory (STM) for objects and congeners interaction in mice AD models. Purpose: In heterozygous McGill-R-Thy1-APP transgenic (Tg+/–) rat model of AD, progressive amyloid pathology is accompanied by cognitive impairment involving long-term memory (LTM) decline. LTM in a novel-object-recognition (NOR) task was impaired in 4-month-old (Tg+/–) male rats, suggesting that they are unable to form/evoke such discriminative memories. Hence, we investigated if AAV-NUsc1 treatment could rescued this memory. Methods: 10-12 weeks-old either Tg or wild type male rats were i.c.v. infused with AAV-NUsc1. Two months later, short-term exploratory behavior, habituation to an open field (OF), object discrimination and LTM for objects were assessed. Results: AAV-NUsc1 treated Tg rats were able to successfully perform the task 24 h after training, denoting recovery of LT discrimination capacity and LTM formation. Wild type rats successfully performed the task either treated or not with AAV-NUsc1. Also, exploration and short-term habituation to an open field was preserved in Tg+/– rats either treated or not. Conclusions: Our present and previous results suggest that AAV-NUsc1 represents a significant advance in gene therapy, supporting the feasibility of immunotherapy using viral vector-mediated NUsc1 gene delivery as a potential therapeutic approach in AD.Evidencias conspicuas respaldan la hipótesis de que la presencia de oligómeros beta-amiloides (AβO) ocasiona un deterioro sináptico y de la memoria en etapas tempranas de la Enfermedad de Alzheimer (AD). Se ha demostrado que el anticuerpo de cadena única y Fragmento variable (scFv) NUsc1, que une selectivamente una subpoblación de AβO, evitó el deterioro de la memoria a corto plazo, inducido por AβO en ratones. Dado que la selectividad de NUsc1 mejora sustancialmente la detección del AβO, y consecuentemente su eficacia terapéutica para AD, se ha desarrollado un vector derivado de Virus Adenoasociado para expresar NUsc1 (AAV-NUsc1) en el cerebro. AAV-NUsc1 rescató la Memoria de Corto Plazo (STM) para el reconocimiento de objetos e interacción con congéneres en ratones modelo de AD. La rata McGill-R-Thy1-APP transgénica heterocigota (Tg+/–) modelo de AD, sufre una patología amiloide progresiva acompañada de deterioro cognitivo, que afecta la Memoria de Largo Plazo (LTM) de Reconocimiento de Objetos (NOR) evitando su formación/evocación. Evaluando si el tratamiento con AAV-NUsc1 podría rescatar la LTM de reconocimiento en ratas macho (Tg+/–) de 4 meses. Ratas macho Tg y de genotipo salvaje (Wt) de 10-12 semanas fueron infundidas i.c.v con AAV-NUsc1. Dos meses más tarde, se evaluaron: el comportamiento exploratorio a corto plazo, la habituación a un Campo Abierto (OF), la discriminación y LTM para objetos. 24 h después del entrenamiento se observó que las ratas Tg tratadas con AAV-NUsc1 recuperaron la capacidad de expresar una LTM y de reconocer objetos novedosos. De manera similar, las ratas Wt tratadas con AAV-NUsc1 y las del grupo control, realizaron la tarea con éxito. La exploración y habituación al OF fueron similares para ratas Tg+/– y Wt, tratadas y control. Nuestros resultados sugieren que AAV-NUsc1 representa un avance significativo en terapia génica, respaldando la viabilidad de la inmunoterapia mediada por vectores virales aportando el gen de NUsc1 como posible enfoque terapéutico para AD.16 páginasapplication/pdfengCorporación Universidad de la CostaColombiahttps://revistascientificas.cuc.edu.co/JACN/article/view/4688Memory recovery through gene therapy with a single chain antibody fragment selective for Aβ oligomers in a model of Alzheimer’s disease in ratsRecuperación de la memoria mediante terapia génica con un fragmento de anticuerpo selectivo para oligómeros de Aβ en un modelo de Alzheimer en ratasArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Journal of Applied Cognitive NeuroscienceAhmad, Z.; Yeap, S.; Ali, A.; Ho, W.; Alitheen, N. & Hamid, M. (2012). ScFv antibody: Principles and clinical application. Clinical and Developmental Immunology, 1–16. https://doi.org/10.1155/2012/980250Akkerman, S.; Blokland, A.; Reneerkens, O.; Van Goethem, N.; Bollen, E.; Gijselaers, H.; Lieben, C.; Steinbusch, H. & Prickaerts, J. (2012). Object recognition testing: Methodological considerations on exploration and discrimination measures. Behavioural Brain Research, 232(2), 335–347. https://doi.org/10.1016/J.BBR.2012.03.022Chabrier, M.; Cheng, D.; Castello, N.; Green, K. & LaFerla, F. (2014). Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer’s disease. Neurobiology of Disease, 64, 107–117. https://doi.org/10.1016/j.nbd.2014.01.007Do Carmo, S. & Cuello, A. (2013). Modeling Alzheimer’s disease in transgenic rats. Molecular Neurodegeneration, 8(1), 1–11. https://doi.org/10.1186/1750-1326-8-37Dunbar, C.; High, K.; Joung, J.; Kohn, D.; Ozawa, K. & Sadelain, M. (2018). Gene therapy comes of age. Science, 359(6372), 1–10. https://doi.org/10.1126/SCIENCE.AAN4672España, J.; Giménez-Llort, L.; Valero, J.; Miñano, A.; Rábano, A.; Rodriguez-Alvarez, J.; LaFerla, F. & Saura, C. A. (2010). Intraneuronal β-Amyloid Accumulation in the Amygdala Enhances Fear and Anxiety in Alzheimer’s Disease Transgenic Mice. Biological Psychiatry, 67(6), 513–521. https://doi.org/10.1016/j.biopsych.2009.06.015Ferreira, S. & Klein, W. (2011). The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiology of Learning and Memory, 96(4), 529–543. https://doi.org/10.1016/J.NLM.2011.08.003Ferrer, I.; Rovira, M.; Sanchez, M.; Rey, M. & Costa-Jussá, F. (2004). Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer’s Disease. Brain Pathology, 14(1), 11–20. https://doi.org/10.1111/j.1750-3639.2004.tb00493.xFischell, J. & Fishman, P. (2021). A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. Frontiers in Neuroscience, 15, 1–20. https://doi.org/10.3389/fnins.2021.747726Fukumoto, H.; Tokuda, T.; Kasai, T.; Ishigami, N.; Hidaka, H.; Kondo, M.; Allsop, D. & Nakagawa, M. (2010). High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. The FASEB Journal, 24(8), 2716–2726. https://doi.org/10.1096/FJ.09-150359Fuller, J.; Stavenhagen, J. & Teeling, J. (2014). New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Frontiers in Neuroscience, 8, 1–10. https://doi.org/10.3389/FNINS.2014.00235Galeano, P.; Martino, P.; Do Carmo, S.; Blanco, E.; Rotondaro, C.; Capani, F.; Castaño, E.; Cuello, A. & Morelli, L. (2014). Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer’s disease. Frontiers in Behavioral Neuroscience, 8, 1–15. https://doi.org/10.3389/fnbeh.2014.00321Georganopoulou, D.; Chang, L.; Nam, J.; Thaxton, C.; Mufson, E.; Klein, W. & Mirkin, C. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proceedings of the National Academy of Sciences, 102(7), 2273–2276. https://doi.org/10.1073/pnas.0409336102Gong, Y.; Chang, L.; Viola, K.; Lacor, P.; Lambert, M.; Finch, C.; Krafft, G. & Klein, W. (2003). Alzheimer’s disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences, 100(18), 10417–10422. https://doi.org/10.1073/PNAS.1834302100Habif, M.; Do Carmo, S.; Báez, M.; Colettis, N.; Cercato, M.; Salas, D.; Acutain, M.; Sister, C.; Berkowicz, V.; Canal, M.; González, T.; Cuello, A. & Jerusalinsky, D. (2021). Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer’s-Like Brain Amyloidosis. Frontiers in Aging Neuroscience, 12, 1–18. https://doi.org/10.3389/fnagi.2020.585873Holliger, P. & Hudson, P. (2005). Engineered antibody fragments and the rise of single domains. Nature Biotechnology, 23(9), 1126–1136. https://doi.org/10.1038/nbt1142Huang, L.; Su, X. & Federoff, H. (2013). Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. International Journal of Molecular Sciences, 14(9), 19109–19127. https://doi.org/10.3390/IJMS140919109Iulita, M.; Allard, S.; Richter, L.; Munter., L.; Ducatenzeiler, A.; Weise, C.; Do Carmo, S.; Klein, W.; Multhaup, G. & Cuello, A. (2014). Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Communications, 2, 1–17. https://doi.org/10.1186/2051-5960-2-61Larson, M. & Lesné, S. (2012). Soluble Aβ oligomer production and toxicity. Journal of Neurochemistry, 120(SUPPL. 1), 125–139. https://doi.org/10.1111/j.1471-4159.2011.07478.xLeon,W.; Canneva,F.;Partridge, V.; Allard,S.;Ferretti,M.;DeWilde, A.; Vercauteren, F.; Atifeh, R.; Ducatenzeiler, A.; Klein, W.; Szyf, M.; Alhonen, L. & Cuello, A. (2010). A Novel Transgenic Rat Model with a Full Alzheimer’s-Like Amyloid Pathology Displays Pre-Plaque Intracellular Amyloid-β-Associated Cognitive Impairment. Journal of Alzheimer’s Disease, 20(1), 113–126. https://doi.org/10.3233/JAD-2010-1349Monnier, P.; Vigouroux, R. & Tassew, N. (2013). In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies, 2(2), 193–208. https://doi.org/10.3390/antib2020193Motulsky, H. & Beutler, E. B. (1989). GraphPad Prism (version 8.0.2) [Software]. GraphPad Software, Inc. https://www.graphpad.com/Mucke, L. & Selkoe, D. (2012). Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harbor Perspectives in Medicine, 2(7), 1–18. https://doi.org/10.1101/cshperspect.a006338Nicoll, J.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H. & Weller, R. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Medicine, 9(4), 448–452. https://doi.org/10.1038/nm840Orgogozo, J.-M.; Gilman, S.; Dartigues, J.-F.; Laurent, B.; Puel, M.; Kirby, L.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.; Boada, M.; Frank, A. & Hock, C. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology, 61(1), 46–54. https://doi.org/10.1212/01.WNL.0000073623.84147.A8Paxinos, G. & Watson, C. (2013). Rat brain in stereotaxic coordinates [7 ed.]. Elsevier.Pimentel, L.; Allard, S.; Do Carmo, S.; Weinreb, O.; Danik, M.; Hanzel, C.; Youdim, M. & Cuello, A. (2015). The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 47(2), 373–383. https://doi.org/10.3233/JAD-143126Sebollela, A.; Cline, E.; Popova, I.; Luo, K.; Sun, X.; Ahn, J.; Barcelos, M.; Bezerra, V.; Lira e Silva, N.; Patel, J.; Pinheiro, N.; Qin, L.; Kamel, J.; Weng, A.; DiNunno, N.; Bebenek, A.; Velasco, P.; Viola, K.; Lacor, P.; Ferreira, S. & Klein, W. (2017). A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers. Journal of Neurochemistry, 142(6), 934–947. https://doi.org/10.1111/JNC.14118Selkoe, D. & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/EMMM.201606210Selles, M.; Fortuna, J.; Cercato, M.; Santos, L.; Domett, L.; Bitencourt, A.; Carraro, M.; Souza, A.; Janickova, H.; Azevedo, C.; Campos, H.; De Souza, J.; AlvesLeon, S.; Prado, V.; Prado, M.; Epstein, A.; Salvetti, A.; Longo, B.; Arancio, O.; Klein, W.; Sebollela, A.; De Felice, F.; Jerusalinsky, D. & Ferreira, S. (2022). AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapse s and rescues memory in Alzheimer models. Molecular Therapy, 31(2), 409–419. https://doi.org/10.1016/j.ymthe.2022.11.002Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; O’Gorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M.; Quintero-Monzon, O.; Scannevin, R.; Arnold, H.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R. & Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323Tomiyama, T.; Matsuyama, S.; Iso, H.; Umeda, T.; Takuma, H.; Ohnishi, K.; Ishibashi, K.; Teraoka, R.; Sakama, N.; Yamashita, T.; Nishitsuji, K.; Ito, K.; Shimada, H.; Lambert, M.; Klein, W. & Mori, H. (2010). A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. Journal of Neuroscience, 30(14), 4845–4856. https://doi.org/10.1523/JNEUROSCI.5825-09.2010Tran, T.; Kim, S.; Gallo, C.; Amaya, M.; Kyees, J. & Narayanaswami, V. (2013). Biochemical and biophysical characterization of recombinant rat apolipoprotein E: Similarities to human apolipoprotein E3. Archives of Biochemistry and Biophysics, 529(1), 18–25. https://doi.org/10.1016/j.abb.2012.10.007Van Dyck, C.; Swanson, C.; Aisen, P.; Bateman, R.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L. & Iwatsubo, T. (2022). Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948Velasco, P.; Heffern, M.; Sebollela, A.; Popova, I.; Lacor, P.; Lee, K.; Sun, X.; Tiano, B.; Viola, K.; Eckermann, A.; Meade, T. & Klein, W. (2012). Synapse-Binding Subpopulationsof Aβ OligomersSensitive to Peptide Assembly Blockers and scFv Antibodies. ACS Chemical Neuroscience, 3(11), 972–981. https://doi.org/10.1021/cn300122k16114LTMAlzheimer’s diseaseGene therapyScFvSingle chain antibody fragmentAβ oligomerMemoria de larga duración MLDEnfermedad de AlzheimerTerapia génicaFragmento de anticuerpo de cadena simpleOligómeros AβPublicationORIGINALMemory recovery through gene therapy with a single.pdfMemory recovery through gene therapy with a single.pdfArtículoapplication/pdf1453150https://repositorio.cuc.edu.co/bitstreams/b09acb4a-40c9-4d6c-9545-576e9449b2c0/download191bd38f77dd3bf5ba3beb3aca987d25MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-814828https://repositorio.cuc.edu.co/bitstreams/47ec96ef-f233-48b9-8c92-a7ebb8a1a3a4/download2f9959eaf5b71fae44bbf9ec84150c7aMD52TEXTMemory recovery through gene therapy with a single.pdf.txtMemory recovery through gene therapy with a single.pdf.txtExtracted texttext/plain56441https://repositorio.cuc.edu.co/bitstreams/deb65333-c02a-4921-a6f2-20c42001f4f1/download44220bf60ca5561946723e077b05af06MD53THUMBNAILMemory recovery through gene therapy with a single.pdf.jpgMemory recovery through gene therapy with a single.pdf.jpgGenerated Thumbnailimage/jpeg13646https://repositorio.cuc.edu.co/bitstreams/a39cb0fe-5f25-4266-8f7a-198694d29706/downloadaf32d53618119e0be2efc17b0743ad64MD5411323/10179oai:repositorio.cuc.edu.co:11323/101792024-09-17 11:08:24.209https://creativecommons.org/licenses/by-nc-nd/4.0/Copyright (c) 2023 Natalia-Claudia Colettis, Maria-Victoria Oberholzer, Magali Cercato, Martin Habif, Maria-Clara Selles, Daniela Salas, Adriano Sebollela, William-L. Klein, Alberto-L. Epstein, Anna Salvetti, Sergio-T. Ferreira, Diana Jerusalinskyopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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